



OPEN **Publisher Correction: Bispecific repurposed medicines targeting the viral and immunological arms of COVID-19**

Published online: 28 September 2021

Martin A. Redhead, C. David Owen, Lennart Brewitz, Amelia H. Collette, Petra Lukacik, Claire Strain-Damerell, Sean W. Robinson, Patrick M. Collins, Philipp Schäfer, Mark Swindells, Chris J. Radoux, Iva Navratilova Hopkins, Daren Fearon, Alice Douangamath, Frank von Delft, Tika R. Malla, Laura Vangeel, Thomas Vercruyssen, Jan Thibaut, Pieter Leyssen, Tu-Trinh Nguyen, Mitchell Hull, Anthony Tumber, David J. Hallett, Christopher J. Schofield, David I. Stuart, Andrew L. Hopkins & Martin A. Walsh

Correction to: *Scientific Reports* <https://doi.org/10.1038/s41598-021-92416-4>, published online 24 June 2021

The original version of this Article contained errors in Table 1, where the molecules were incorrectly displayed. The original Table 1 and accompanying legend appear below.

The original Article has been corrected.













							
Compound number	Generic name	R ¹	R ²	R ³	R ⁴	R ⁵	IC ₅₀ (μM) (range)
8	Tarloxotinib	Br	F	N	N		0.3 (0.1–0.5)
9	Tarloxotinib (ac)	Br	F	N	N		0.3 (0.1–0.4)
10	Pelitinib	Cl	Cl				> 100*
11	Afatinib	Cl	Cl	N			12 (11–16)
12	Dacomitinib	Cl	Cl	N			4 (3–5)
13	Gefitinib	Cl	Cl	N			7 (6–11)

Table 1. Structure–activity relationship of 4-aminoquinazoline EGFR inhibitors against SARS-CoV-2 PL^{pro}.
*The range could not be established due to lack of potency.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2021